For over three decades, UCSF has had a Graduate Program in Pharmaceutical Chemistry (PC). This widely recognized and highly successful program has supplied a legion of outstanding scientists to the academic and industrial research community. For over two decades the program has been supported by the NIH training grant in Pharmaceutical Chemistry and Biopharmaceutical Sciences. The current application is a competitive renewal of this training grant. The application has been re-titled to Pharmaceutical Sciences and Pharmacogenomics (PSPG) to reflect the evolution of the training program in response to exciting scientific developments in the area of genomics that have far-reaching implications to the pharmaceutical and pharmacological sciences. The PSPG Graduate Program is a cross-disciplinary program that represents the merger at UCSF of scientists working in pharmaceutical sciences and contemporary genetics. This program broadly encompasses the areas of molecular pharmacology related to drug action, drug transport, drug metabolism and drug/gene delivery. The Program also includes the areas of kinetic/dynamic modeling, pharmacogenomics and bioinformatics applied to pharmacogenomics. The program offers in-depth training in these areas through a core curriculum that also encourages breadth of knowledge about these fields. In the past integrative approach has resulted in Ph.D. graduates who have the interdisciplinary insights and quantitative scientific tools that are characteristic of excellent scientists. Consequently our graduates are in high demand in academia, industry and government. With the identification and mapping of nearly 100,000 genes through the Human Genome Project, it is anticipated that there will be a major impact on diagnosis and treatment of human disease. There is enormous excitement in the pharmaceutical sciences and in human genetics, as people in each of these historically separate areas realize that understanding genetic contributions to drug response is an exciting frontier for both groups. Our program is one of the very few in the World with faculty expertise that spans these fields hence we believe the training program is ideally situated to provide the future scientific leaders in these scientific areas.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
2T32GM007175-26
Application #
6409838
Study Section
National Institute of General Medical Sciences Initial Review Group (BRT)
Program Officer
Preusch, Peter C
Project Start
1982-07-01
Project End
2007-06-30
Budget Start
2002-07-01
Budget End
2003-06-30
Support Year
26
Fiscal Year
2002
Total Cost
$151,677
Indirect Cost
Name
University of California San Francisco
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Bowman, C M; Benet, L Z (2018) An examination of protein binding and protein-facilitated uptake relating to in vitro-in vivo extrapolation. Eur J Pharm Sci 123:502-514
Chan, Rosa; Benet, Leslie Z (2018) Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI. Toxicol Sci 162:499-508
Bisanz, Jordan E; Spanogiannopoulos, Peter; Pieper, Lindsey M et al. (2018) How to Determine the Role of the Microbiome in Drug Disposition. Drug Metab Dispos 46:1588-1595
Eclov, Rachel J; Kim, Mee J; Smith, Robin et al. (2018) Rare Variants in the ABCG2 Promoter Modulate In Vivo Activity. Drug Metab Dispos 46:636-642
Chang, Matthew T; Penson, Alexander; Desai, Neil B et al. (2018) Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clin Cancer Res 24:1965-1973
Li, M; Seiser, E L; Baldwin, R M et al. (2018) ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J 18:35-42
Rashkin, Sara R; Chua, Katherina C; Ho, Carol et al. (2018) A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance). Clin Pharmacol Ther :
Dolor, Aaron; Kierstead, Paul; Dai, Zhipeng et al. (2018) Sterol-modified PEG lipids: alteration of the bilayer anchoring moiety has an unexpected effect on liposome circulation. Chem Commun (Camb) 54:11949-11952
Vora, Bianca; Wang, Aolin; Kosti, Idit et al. (2018) Meta-Analysis of Maternal and Fetal Transcriptomic Data Elucidates the Role of Adaptive and Innate Immunity in Preterm Birth. Front Immunol 9:993
Yee, Sook Wah; Brackman, Deanna J; Ennis, Elizabeth A et al. (2018) Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium. Clin Pharmacol Ther 104:803-817

Showing the most recent 10 out of 193 publications